BCTX Stock Analysis: Buy, Sell, or Hold?
BCTX - Briacell Therapeutics Corp. Common Shares
$3.46
-0.61 (-14.99%)
âŧ
5d:
+2.06%
30d:
-3.35%
90d:
-0.86%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Jun 15, 2026
0d
Get Alerted When BCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BCTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BCTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BCTX is currently trading at $3.46, which is considered slightly low relative to its 30-day fair value range of $3.39 to $3.77.
Technical Outlook: Technically, BCTX is in a downtrend. The price is currently testing key support at $3.36. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.0% recently.
Market Sentiment: BCTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $150.00 (+4235.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCTX is in a downtrend. The price is currently testing key support at $3.36. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.0% recently.
Market Sentiment: BCTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $150.00 (+4235.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.39 -
$3.77
Company Quality Score
42/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BEARISH: Downward momentum (-15.0%)
- BULLISH: Trading 4235.3% below Wall St target ($150.00)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.39 -
$3.77
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.36
Resistance Level
$4.18
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.02
Wall Street Target
$150.00
(+4235.3%)
Share & Embed Analysis
Last updated: August 24, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 37 SELL |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 47 HOLD |
